CEA

Micromet, Inc. Reports Second Quarter 2009 Financial Results

...al product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting cea for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration ...

Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203

...al product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting cea for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration ...

Defeating nicotine's double role in lung cancer

...te for Research, Hospitalization and Health Care (IRCCS), Catholic University, Campus Biomedico University in Rome, Mario Negri Institute in Milan and cea Gyf sur Yvette in France showed in past research that an antagonist of nicotine acetylcholine receptors (nAChRs), may serve as an anticancer agent. Th...

VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque

...linical trials, including without limitation, with respect to the safety and efficacy of VIA-2291; -- if the results of the ACS and cea studies, upon further review and analysis, are revised or negated by authorities or by later stage clinical trials; -- o...

Measles virus may be effective prostate cancer treatment

...an excellent safety record with millions of vaccine doses having been safely administered in over 40 years of use. Repeated measurements of the marker cea (carcinoembryonic antigen, produced when the virus replicates) following MV-CEA treatment can be performed via a simple blood test, and can potentiall...

AdvaMed 2008 Sponsor Participation Increases by 52%

...nt Track) -- Powell Goldstein LLP (Emerging Company Issues Track) -- REED Exhibitions (Global Business Issues Track) Collateral Sponsors: -- cea Technologies -- Ernst & Young -- Georgia Hidden List Department of Economic Development -- Korn/Ferry International -- MedNet Solut...

Micromet, Inc. Reports Second Quarter 2008 Financial Results

..., Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, cea and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and com...

FDA Grants AMDL Clearance to Market the AMDL-ELISA DR-70(R) (FDP) Blood Test for Monitoring Colorectal Cancer

...et that the FDA has granted for any monitoring product for CRC since January 14, 1982 when Carcinoembryonic Antigen (CEA) was approved. Until now, the cea test has been the only accepted method cleared in the U.S. DR-70 (FDP) offers a new test that can monitor CRC tumors post-surgery. The DR-70 (FDP) t...

Charterhouse Group Partners with MTS Health Investors and Highlander Partners to Acquire Chamberlin Edmonds & Associates, Inc., a Leading Provider of Eligibility Services to Hospitals

...y determination services to America's hospitals. cea guides uninsured patients through complex applicat...Led by Ulrich and his exceptional management team, cea provides tremendous value to its hospital customer...s across the country. We are quite excited to help cea continue its impressive growth, and we look forwar...

Partnerships Effective Communicators of Cancer Advances

...planning. Nearly all the patients (93 percent) received appropriate surveillance with history and physical exams at suggested intervals and routine cea testing. Abdominal and pelvic surveillance CT was performed in 78 percent of patients. "We found a drop-off in compliance (49 percent) regarding th...

More>>

CEA in Medical Technology

Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA

GAITHERSBURG, Md. and CARLSBAD, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. and MedImmune, Inc. today announced data from a preclinical study in which BiTE(R) molecules targeting carcinoembryonal antigen (CEA) were shown to prevent subcutaneous tumor growth and formation of lun...

VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease

...ompany reviewed safety and biologic activity data from the VIA-2291 Phase 2 cea and ACS trials with the FDA and received guidance including suggestions fro...o the safety and efficacy of VIA-2291; -- if the results of the ACS and cea studies, upon further review and analysis, are revised or negated ...

AlphaVax Announces Promising Results in Melanoma Studies

...c, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. A phase I/II clinical trial for a cea tumor vaccine is currently ongoing at Duke University and a Her2 breast cancer clinical trial is planned for later this year. In addition to cancer ...

VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease

...ment and progression of atherosclerosis. ACS and cea Study Designs The ACS Phase 2 study of VIA-2291 ...tatistics group at Montreal Heart Institute. The cea Phase 2 study evaluated VIA-2291's effect on ather...mmation in 50 patients scheduled for elective CEA. cea is a surgical procedure to remove plaque from the ...

Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells

..., Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, cea and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and com...

VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial

... a subset of patients. Patients in the study are treated once daily with one of three dose levels of VIA-2291 or placebo. In addition to the ACS and cea studies, VIA is conducting a third Phase 2 clinical trial, the FDG-PET Trial. Enrollment in this trial is ongoing and endpoints in this study include ...

VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008

... Topline Data from Phase 2 cea and ACS Clinical Trials to be Released Concurrent with A...mbargo policy, the company will announce the proof of concept data from its cea and ACS trials concurrent with the AHA sessions. The presentation detai...

Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy

..., Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, cea and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and com...

Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE

..., Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, cea and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and com...

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

...gastrointestinal cancers. Three additional BiTE antibodies, targeting CD33, cea and MCSP, respectively, are in preclinical development. About Micromet, I... of patients with cancer. Three additional BiTE antibodies, targeting CD33, cea and MCSP, respectively, are in preclinical development. In addition, Microm...

CEA in Biological Technology

Micromet Closes $80.5 Million Public Offering of Common Stock

...al product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting cea for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...al product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting cea for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration ...

Micromet Announces Pricing of Public Offering of Common Stock

...al product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting cea for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration ...

Micromet Announces Public Offering of Common Stock

...al product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting cea for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

...al product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting cea for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration ...

VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ

...results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291; if the results of the ACS and cea studies, upon further review and analysis, are revised, interpreted differently by regulatory authorities or negated by later stage clinical trials; ...

Micromet Added to Russell 3000 Index

...al product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting cea for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration ...

VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation

...linical trials, including without limitation, with respect to the safety and efficacy of VIA-2291; -- if the results of the ACS and cea studies, upon further review and analysis, are revised or negated by authorities or by later stage clinical trials; -- o...

VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients

...linical trials, including without limitation, with respect to the safety and efficacy of VIA-2291; -- if the results of the ACS and cea studies, upon further review and analysis, are revised or negated by authorities or by later stage clinical trials; -- o...

Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program

...ata Solutions Pathworks Diagnostics nominated by Univa UD Genentech nominated by Dolcera AstraZeneca nominated by Thermo Fisher Scientific cea (Commissariat à l'Energie Atomique) nominated by Bio-Modeling Systems Criteria and Judging Awards finalists and winners were selected for t...